Montes Claros

Researchers are evaluating LXE408 in adults with chronic Chagas disease without severe organ dysfunction. This study is a phase 2, randomized, participant- and investigator-blinded, controlled trial with four treatment groups. The goal is to assess the effectiveness, safety, tolerability, pharmacokinetics, and pharmacodynamics of LXE408 compared to placebo and benznidazole in clearing or reducing parasites in the blood. Participants are randomly assigned to one of four groups LXE408 taken orally for 28 days, LXE408 for 14 days followed by placebo for 14 days, placebo for 28 days, or benznidazole for 60 days. The study monitors parasite clearance using PCR tests at multiple time points, including early clearance at days 7, 14, and 28, and sustained clearance for up to 12 months. Pharmacokinetic measurements of LXE408 are also taken during treatment. Participants will undergo regular assessments including PCR testing for parasite levels at months 2, 4, 6, and 12, serology tests at months 6 and 12, and monitoring for adverse events up to 48 months. Safety evaluations and pharmacokinetic blood samples are collected during treatment. The total study duration extends up to 6 years including long-term follow-up to track treatment impact and participant health.

Researchers are developing a registry of Brazilian patients with hereditary cardiovascular diseases by combining clinical information and genetic data. The study aims to identify which genes are most commonly affected and the frequency of these genetic changes within this population. The registry will help advance understanding and healthcare for hereditary heart conditions in Brazils public health system. Participants will be interviewed during their routine medical visits, and their DNA will be collected using buccal swabs for whole genome sequencing. This observational study does not involve any treatment but focuses on gathering detailed genetic and clinical data to better characterize hereditary cardiovascular diseases. The study is planned to run for 30 months starting from April 2025. During the study, participants will provide information through interviews and give DNA samples for sequencing. Researchers will measure diagnostic yield, genetic diversity, and variant frequency over the 30 months. The study does not involve additional interventions beyond data and sample collection, and participants will continue their usual medical care throughout the study period.